stonks4u
Sign up free
MNPR logo

MNPR Monopar Therapeutics Inc.

NASDAQ · Biotechnology · Healthcare

$113.04
+2.63 (+2.38%)

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressi…

Market Cap: $757.26Mwww.monopartx.com

Price (90d)

No price history yet — the daily price refresh runs once a day.

Signal Score (90d)

100
100
Aug 12Aug 12

Quote

Day Range
$107.11 – $113.56
52-Week Range
$29.18 – $124.82
Volume
$165.7K
Market Cap
$757.26M
50-Day Avg
$95.17
200-Day Avg
$72.69
Prev Close
$110.41
Open
$108.03

Valuation & Ratios

P/E Ratio
-35.30
EPS
$-1.85
P/B Ratio
3.51
P/S Ratio
0.00
Debt/Equity
0.00
Current Ratio
51.35
Dividend Yield
+0.0%
Gross Margin
+0.0%

Returns & Efficiency

Return on Equity
-10.0%
Return on Assets
-9.7%
FCF Yield
-2.5%
EV/EBITDA
-30.78

Revenue & Net Income (Annual)

Fiscal YearRevenueNet IncomeEPS
2025$0.00$-13.72M$-1.85
2024$0.00$-15.59M$-1.36
2023$0.00$-8.40M$-0.58
2022$0.00$-10.52M$-0.83
2021$0.00$-9.10M$-0.73

Social Signal Score

50
5d
50
1 mentions
—
30d
50
1 mentions
—
60d
50
1 mentions
—
90d
50
1 mentions
—
news: 1

Earnings

Thu, Nov 12(in 3 months)

Consensus estimate $-0.80 per share

4of 7 quarters beat consensus

Typical surprise +3.5% (median, so one quarter with a near-zero estimate can't distort it)

  • Wed, Aug 12$-0.62 vs $-0.64beat
  • Thu, May 14$-0.46 vs $-1.06beat
  • Fri, Mar 27$-0.61 vs $-0.51miss
  • Thu, Nov 13$-0.48 vs $-0.46miss
  • Tue, Aug 12$-0.35 vs $-0.47beat
  • Tue, May 13$-0.38 vs $-0.65beat

Estimates and results for MNPR via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.

Valuation

MNPRhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.

Mentions (1)

  • Newsglobenewswire.com·3d ago·Neutral

    Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates WILMETTE, Ill., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced second quarter 2026 financial results and provided business updates.

    View source ↗